TABLE 2.

Baseline clinical characteristics of patients with bacteremia caused by gram-negative bacilli with Pitt bacteremia scores of ≥4 by therapy type

Variable	Value		P value
	Single therapy (n = 79)	Combination therapy (n = 90)
Age (yr) [median (IQRa)]	67 (53-78)	67 (54-76)	0.69
Gender [n (%)]			0.23
Female	23 (29)	34 (38)
Male	56 (71)	56 (62)
Diabetes mellitus [n (%)]	17 (22)	22 (24)	0.65
End stage renal disease [n (%)]	2 (3)	6 (7)	0.21
End stage liver disease [n (%)]	10 (13)	7 (8)	0.29
Active cancer [n (%)]	34 (43)	39 (43)	0.97
Cancer type [n (%b)]			0.02
Hematologic tumor	8 (24)	21 (54)
Solid tumor	26 (76)	18 (46)
Immunocompromised host [n (%)]	13 (16)	29 (32)	0.02
Type of immunosuppression
Neutropenia [n (%)]	3 (4)	12 (13)	0.03
Recent chemotherapy [n (%)]	8 (10)	17 (19)	0.11
Corticosteroids [n (%)]	5 (6)	10 (11)	0.28
Transplant recipient [n (%)]	4 (5)	11 (12)	0.10
Immunosuppressive therapy [n (%)]	4 (5)	9 (10)	0.23
Recent surgery [n (%)]	45 (58)	42 (47)	0.15
Central venous catheter [n (%)]	37 (48)	46 (51)	0.69
Foley catheter [n (%)]	45 (57)	39 (43)	0.08
Charlson comorbidity score [median (IQR)]	4.0 (1.0-8.0)	4.0 (2.0-7.0)	0.95
Serum creatinine (mg/dl) [median (IQR)]	1.5 (1.1-2.1)	1.6 (1.1-2.5)	0.18
Prior antibiotic therapy [n (%)]	26 (33)	26 (29)	0.57
Gram-negative organism [n (%)]			0.76
E. coli	19 (24)	23 (26)
Klebsiella species	15 (19)	21 (23)
Pseudomonas species	11 (14)	16 (18)
Enterobacter species	15 (19)	13 (14)
Other	19 (24)	17 (19)
Acquisition site of bacteremia [n (%)]			0.28
Nosocomial	47 (59)	44 (49)
Health care associated	18 (23)	30 (33)
Community acquired	14 (18)	16 (18)
Primary source of bacteremia [n (%)]			0.68
Urinary	17 (22)	29 (32)
Gastrointestinal	17 (22)	13 (14)
Respiratory	18 (23)	18 (20)
Line related	6 (8)	7 (8)
Skin and soft tissue	1 (1)	1 (1)
Unknown primary source	20 (25)	22 (24)
Resistance to beta-lactam antibiotic [n (%)]	5 (6)	1 (1)	0.10

^aIQR, interquartile range.

^bAmong subjects with active cancer.